Breast Cancer
- kaggle.com
Updated Aug 8, 2022
Share
Facebook
Twitter
EmailClick to copy linkLink copiedCiteReihaneh Namdari (2022). Breast Cancer [Dataset]. https://www.kaggle.com/datasets/reihanenamdari/breast-cancerCroissantCroissant is a format for machine-learning datasets. Learn more about this at mlcommons.org/croissant.Dataset updatedAug 8, 2022Dataset provided byKaggleAuthorsReihaneh NamdariLicenseAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automaticallyDescriptionThis dataset of breast cancer patients was obtained from the 2017 November update of the SEER Program of the NCI, which provides information on population-based cancer statistics. The dataset involved female patients with infiltrating duct and lobular carcinoma breast cancer (SEER primary cites recode NOS histology codes 8522/3) diagnosed in 2006-2010. Patients with unknown tumour size, examined regional LNs, positive regional LNs, and patients whose survival months were less than 1 month were excluded; thus, 4024 patients were ultimately included.
- p
BREAST CANCER - Dataset - CKAN
- data.poltekkes-smg.ac.id
Updated Oct 7, 2024ShareFacebookTwitterEmailClick to copy linkLink copiedCite(2024). BREAST CANCER - Dataset - CKAN [Dataset]. https://data.poltekkes-smg.ac.id/dataset/breast-cancerDataset updatedOct 7, 2024LicenseAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automaticallyDescriptionThis dataset of breast cancer patients was obtained from the 2017 November update of the SEER Program of the NCI, which provides information on population-based cancer statistics. The dataset involved female patients with infiltrating duct and lobular carcinoma breast cancer (SEER primary cites recode NOS histology codes 8522/3) diagnosed in 2006-2010. Patients with unknown tumour size, examined regional LNs, positive regional LNs, and patients whose survival months were less than 1 month were excluded; thus, 4024 patients were ultimately included.
Seer Breast Cancer Data
- zenodo.org
- ieee-dataport.org
- +1more
Updated Jul 22, 2021ShareFacebookTwitterEmailClick to copy linkLink copiedCiteZhandos Sembay; Zhandos Sembay (2021). Seer Breast Cancer Data [Dataset]. http://doi.org/10.5281/zenodo.5120960Unique identifierhttps://doi.org/10.5281/zenodo.5120960Dataset updatedJul 22, 2021AuthorsZhandos Sembay; Zhandos SembayLicenseAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automaticallyDescriptionAbstract:
This dataset of breast cancer patients was obtained from the 2017 November update of the SEER Program of the NCI, which provides information on population-based cancer statistics. The dataset involved female patients with infiltrating duct and lobular carcinoma breast cancer (SEER primary cites recode NOS histology codes 8522/3) diagnosed in 2006-2010. Patients with unknown tumor size, examined regional LNs, regional positive LNs, and patients whose survival months were less than 1 month were excluded; thus, 4024 patients were ultimately included.
Inspiration:
This dataset uploaded to U-BRITE for "AI against CANCER DATA SCIENCE HACKATHON"
https://cancer.ubrite.org/hackathon-2021/
Acknowledgements
JING TENG, January 18, 2019, "SEER Breast Cancer Data", IEEE Dataport, doi: https://dx.doi.org/10.21227/a9qy-ph35.
https://ieee-dataport.org/open-access/seer-breast-cancer-data
U-BRITE last update date: 07/21/2021
Not seeing a result you expected?
Learn how you can add new datasets to our index.
FacebookTwitterEmailBreast Cancer
Seer Breast Cancer Data - Labeled
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
This dataset of breast cancer patients was obtained from the 2017 November update of the SEER Program of the NCI, which provides information on population-based cancer statistics. The dataset involved female patients with infiltrating duct and lobular carcinoma breast cancer (SEER primary cites recode NOS histology codes 8522/3) diagnosed in 2006-2010. Patients with unknown tumour size, examined regional LNs, positive regional LNs, and patients whose survival months were less than 1 month were excluded; thus, 4024 patients were ultimately included.